D. E. Shaw & Co., Inc. Intercept Pharmaceuticals, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	SELL	$13.37 - $17.79 $549,507 - $731,169	-41,100 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$19.33 - $37.75 $1.4 Million - $2.74 Million	-72,600 Reduced 63.85%	41,100 $949,000
Q2 2020 Aug 14, 2020	BUY	$46.7 - $92.04 $467,000 - $920,400	10,000 Added 9.64%	113,700 $5.45 Million
Q1 2020 May 15, 2020	BUY	$48.35 - $118.68 $483,500 - $1.19 Million	10,000 Added 10.67%	103,700 $6.53 Million
Q4 2019 Feb 14, 2020	BUY	$57.36 - $124.1 $636,696 - $1.38 Million	11,100 Added 13.44%	93,700 $11.6 Million

Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $3.24 Million - $4.26 Million	35,300 Added 74.63%	82,600 $9.24 Million
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $1.85 Million - $2.73 Million	21,600 Added 84.05%	47,300 $4.77 Million
Q3 2018 Nov 14, 2018	BUY	$88.49 - $127.55 $1.39 Million - $2 Million	15,700 Added 157.0%	25,700 $3.25 Million
Q1 2018 May 15, 2018	BUY	$52.72 - $67.25 $527,200 - $672,500	10,000 New	10,000 $615,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.